Home - News ( United States | United Kingdom | Italy | Germany ) - Football scores

Showing content from https://pubmed.ncbi.nlm.nih.gov/11039452/ below:

FDG PET in the evaluation of the aggressiveness of pulmonary adenocarcinoma: correlation with histopathological features

Clinical Trial

Affiliations

• ¹ Department of Radiology, Kanazawa Medical University, Japan. h550208@kanazawa-med.ac.jp

• PMID: 11039452
• DOI: 10.1097/00006231-200008000-00002

Item in Clipboard

Clinical Trial

K Higashi et al. Nucl Med Commun. 2000 Aug.

• ¹ Department of Radiology, Kanazawa Medical University, Japan. h550208@kanazawa-med.ac.jp

• PMID: 11039452
• DOI: 10.1097/00006231-200008000-00002

Item in Clipboard

2-[Fluorine-18]fluoro-2-deoxy-d-glucose (FDG) uptake within the primary lesion correlates with survival on positron emission tomography (PET) studies of patients with non-small cell lung cancer. The more metabolically active the tumour, the worse the outcome. The aim of this study was to determine whether a correlation exists between aggressiveness as determined by pathology and the findings of FDG PET in pulmonary adenocarcinoma. Thirty-five patients with 38 adenocarcinomas of the lung were studied. All patients underwent thoracotomy within 4 weeks of the FDG PET study. For semiquantitative analysis, standardized uptake values (SUVs) were calculated. Patients were classified into high SUV (> or = 4.0) and low SUV (<4.0) groups. The degree of FDG uptake (SUVs) in primary lung lesions was correlated with the histopathological features of aggressiveness (pleural involvement, vascular invasion or lymphatic permeation). The mean SUV of aggressive adenocarcinomas (4.36+/-1.94, n = 22) was higher than that of non-aggressive ones (1.53+/-0.88, n = 16) (P < 0.0001). Tumours with a high FDG uptake have a significantly higher likelihood of aggressiveness than those with a low FDG uptake (P = 0.0004). Analysis by the Kaplan-Meier methods revealed that the groups had different prognoses (log-rank test, P = 0.0099). The high SUV group had a significantly worse prognosis. In conclusion, a correlation was seen between aggressiveness as determined by pathology and glucose metabolism as measured by FDG PET in adenocarcinoma of the lung. FDG PET may be used as a non-invasive diagnostic technique in measuring aggressiveness and prognosis in patients with pulmonary adenocarcinoma.

PubMed Disclaimer

• Correlation of Glut-1 glucose transporter expression with.

  Higashi K, Ueda Y, Sakurai A, Wang XM, Xu L, Murakami M, Seki H, Oguchi M, Taki S, Nambu Y, Tonami H, Katsuda S, Yamamoto I. Higashi K, et al. Eur J Nucl Med. 2000 Dec;27(12):1778-85. Eur J Nucl Med. 2000. PMID: 11189940

• P-glycoprotein expression is associated with FDG uptake and cell differentiation in patients with untreated lung cancer.

  Higashi K, Ueda Y, Ikeda R, Kodama Y, Guo J, Matsunari I, Oguchi M, Tonami H, Katsuda S, Yamamoto I. Higashi K, et al. Nucl Med Commun. 2004 Jan;25(1):19-27. doi: 10.1097/00006231-200401000-00004. Nucl Med Commun. 2004. PMID: 15061261 Clinical Trial.

• Fluorine-18-FDG PET imaging is negative in bronchioloalveolar lung carcinoma.

  Higashi K, Ueda Y, Seki H, Yuasa K, Oguchi M, Noguchi T, Taniguchi M, Tonami H, Okimura T, Yamamoto I. Higashi K, et al. J Nucl Med. 1998 Jun;39(6):1016-20. J Nucl Med. 1998. PMID: 9627336

• 11C-acetate PET imaging of lung cancer: comparison with 18F-FDG PET and 99mTc-MIBI SPET.

  Higashi K, Ueda Y, Matsunari I, Kodama Y, Ikeda R, Miura K, Taki S, Higuchi T, Tonami H, Yamamoto I. Higashi K, et al. Eur J Nucl Med Mol Imaging. 2004 Jan;31(1):13-21. doi: 10.1007/s00259-003-1326-7. Epub 2003 Oct 22. Eur J Nucl Med Mol Imaging. 2004. PMID: 14574513 Clinical Trial.

• Dynamic prognostication using conditional survival analysis for patients with operable lung adenocarcinoma.

  Kim W, Lee HY, Jung SH, Woo MA, Kim HK, Choi YS, Kim J, Zo JI, Shim YM, Han J, Jeong JY, Choi JY, Lee KS. Kim W, et al. Oncotarget. 2017 May 9;8(19):32201-32211. doi: 10.18632/oncotarget.12920. Oncotarget. 2017. PMID: 27793026 Free PMC article.

• The impact of the COVID-19 pandemic on oncological disease extent at FDG PET/CT staging: the ONCOVIPET study.

  Caldarella C, Cocciolillo F, Taralli S, Lorusso M, Scolozzi V, Pizzuto DA, Calcagni ML, Rufini V, Guido D, Palluzzi F, Giacò L, Giordano A, Leccisotti L. Caldarella C, et al. Eur J Nucl Med Mol Imaging. 2022 Apr;49(5):1623-1629. doi: 10.1007/s00259-021-05629-0. Epub 2021 Dec 8. Eur J Nucl Med Mol Imaging. 2022. PMID: 34877609 Free PMC article.

• The role of (18)F-FDG PET in the differentiation between lung metastases and synchronous second primary lung tumours.

  Dijkman BG, Schuurbiers OC, Vriens D, Looijen-Salamon M, Bussink J, Timmer-Bonte JN, Snoeren MM, Oyen WJ, van der Heijden HF, de Geus-Oei LF. Dijkman BG, et al. Eur J Nucl Med Mol Imaging. 2010 Nov;37(11):2037-47. doi: 10.1007/s00259-010-1505-2. Epub 2010 Jun 10. Eur J Nucl Med Mol Imaging. 2010. PMID: 20533031 Free PMC article.

RetroSearch is an open source project built by @garambo | Open a GitHub Issue

Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo

HTML: 3.2 | Encoding: UTF-8 | Version: 0.7.3